| 000 | 00920 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250517223712.0 | ||
| 264 | 0 | _c20190917 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1776-260X | ||
| 024 | 7 |
_a10.1007/s11523-018-0575-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAgulnik, Mark | |
| 245 | 0 | 0 |
_aGrowing Role of Regorafenib in the Treatment of Patients with Sarcoma. _h[electronic resource] |
| 260 |
_bTargeted oncology _c08 2018 |
||
| 300 |
_a417-422 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPhenylurea Compounds _xpharmacology |
| 650 | 0 | 4 |
_aPyridines _xpharmacology |
| 650 | 0 | 4 |
_aSarcoma _xdrug therapy |
| 700 | 1 | _aAttia, Steven | |
| 773 | 0 |
_tTargeted oncology _gvol. 13 _gno. 4 _gp. 417-422 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11523-018-0575-0 _zAvailable from publisher's website |
| 999 |
_c28558619 _d28558619 |
||